目的:探究米非司酮治疗围绝经期功能性子宫出血的作用及安全性.方法:选取2020年4月-2021年3月期间我院收治的围绝经期功能性子宫出血患者76例,将其依据随机数列表法均分为参照组(38例),研究组(38例),分别接受常规治疗以及米非司酮治疗,对比2组患者治疗前后激素水平变化情况、子宫体积、子宫内膜厚度以及不良反应发生率.结果:2组患者治疗前激素水平、子宫体积以及子宫内膜厚度均无显著差异(P＞0.05),经治疗后,2组患者激素水平、子宫体积以及子宫内膜厚度均显著下降,研究组患者各项指标下降更为明显,且研究“,”Objective:To investigate the effect and safety of mifepristone in treating perimenopausal functional uterine bleeding.Methods:76 patients with postmenopausal functional uterine bleeding admitted in our hospital from April 2020 to March 2021 were randomly divided into reference group (38 cases) and study group (38 cases) according to random number list method. They received conventional treatment and mifepristone treatment respectively, and the uterine volume of patients in the two groups before and after treatment was compared Endometrial thickness and incidence of adverse reactions. Results:There was no significant difference in hormone level, uterine volume and endometrial thickness between the two groups before treatment (P ＞ 0.05). After treatment, the hormone level, uterine volume and endometrial thickness of the two groups decreased significantly, and the indexes of the study group decreased more significantly, and the incidence of adverse reactions in the study group was significantly lower than that in the reference group, the difference was statistically significant (P＜0.05).Conclusion:Mifepristone is effective in the treatment of perimenopausal functional uterine bleeding. It can fully improve the hormone level of patients, alleviate uterine bleeding and improve endometrial thickness. At the same time, the adverse reactions of patients are lower and the drug safety is higher. This treatment method has significant application significance and is worthy of clinical promotion.